Anti-Inflammatory Medications for Retinal Conditions
Understanding Retinal Inflammation
The retina is a thin layer of light-sensitive tissue at the back of the eye. When inflammation occurs in or around the retina, it can trigger a chain of harmful effects. Fluid can accumulate in the macula, the central part of the retina responsible for sharp vision. Blood vessels may begin to leak. The photoreceptors (the cells that capture light) can become damaged.
These changes can lead to blurred or distorted vision. Left untreated, chronic inflammation may cause lasting harm. Timely management of inflammation is one of the most important steps in preserving vision.
Prostaglandins are chemicals the body produces from a fatty acid called arachidonic acid. Inside the eye, prostaglandins disrupt the blood-ocular barrier, widen blood vessels, and attract immune cells into the area. They also interact with and amplify other inflammatory signals. One of these signals is vascular endothelial growth factor (VEGF), a protein that drives abnormal blood vessel growth and leakage.
By blocking prostaglandin production, anti-inflammatory medications can reduce swelling, limit vascular leakage, and help stabilize the retinal environment.
Many retinal conditions have an inflammatory component. These include diabetic macular edema (DME), macular edema from retinal vein occlusion (RVO), and noninfectious uveitis affecting the back of the eye. Cystoid macular edema (CME) after cataract surgery also involves inflammation. An estimated 19.8 million Americans have age-related macular degeneration. Another 9.6 million have diabetic retinopathy. Both conditions can involve inflammation that threatens vision (Retina Today, 2025).
Who Is Affected and Risk Factors
Several factors increase the chance that inflammation will affect the retina. Understanding these risk factors helps patients and retina specialists plan appropriate monitoring and treatment. Key risk factors include:
- Diabetes mellitus, which raises the relative risk of inflammatory complications and macular edema by roughly 2.87 times (AAO, 2023)
- A history of retinal vein occlusion, the strongest predictor of postoperative CME in one study, with an odds ratio of 47.12 (AAO, 2023)
- Pre-existing uveitis or other autoimmune conditions
- Age-related macular degeneration
- Use of certain prostaglandin-based eye drops before surgery
- A weakened immune system from medications, cancer treatment, or infections such as HIV/AIDS
Cataract surgery is one of the most common operations performed worldwide. While it is generally very safe, inflammation after the procedure can lead to cystoid macular edema. In this condition, fluid collects in the macula. Using data from more than 3 million cataract surgeries performed in the United States between 2016 and 2019, the overall incidence of postoperative CME was 0.8% (AAO, 2023).
Patients with a history of retinal vein occlusion, epiretinal membrane, or preoperative prostaglandin eye drop use have a higher risk. This is one reason retina specialists may recommend anti-inflammatory medications before or after cataract surgery for certain patients.
Diabetes is one of the leading causes of vision loss worldwide. An estimated 537 million adults globally are living with diabetes (International Diabetes Federation, 2021). Diabetic retinopathy, a common complication, involves damage to the small blood vessels in the retina. This damage triggers an inflammatory response that can lead to fluid leakage and macular edema. Among patients seen at retina practices, 8.8% had diabetic macular edema and 8.3% had diabetic retinopathy without macular edema (IRIS Registry, 2021).
Types of Anti-Inflammatory Medications
Nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, are one of the two main categories of anti-inflammatory treatment used in eye care. These medications work by blocking enzymes that produce prostaglandins. By reducing prostaglandin levels, NSAIDs help decrease pain, swelling, and inflammation.
Several topical NSAIDs are available in eye drop form. These include ketorolac, diclofenac, nepafenac, bromfenac, and flurbiprofen. Each has slightly different properties. For example, nepafenac ophthalmic suspension 0.1% (Nevanac) is a prodrug. This means it converts into its active form after it enters the eye. This design may allow better penetration into the retina.
Topical NSAIDs are most commonly used around the time of cataract surgery. They help manage pain, reduce sensitivity to light, and prevent the pupil from constricting during surgery. They also lower the risk of postoperative cystoid macular edema. In recent years, newer formulations have raised interest in whether topical NSAIDs may also play a role in treating other retinal conditions involving inflammation.
Corticosteroids are powerful anti-inflammatory and immunosuppressive medications. They work differently from NSAIDs. Corticosteroids inhibit an enzyme called phospholipase A2. This blocks the production of both prostaglandins and leukotrienes (another group of inflammatory chemicals). They also suppress multiple pathways involved in inflammation, blood vessel leakage, and immune cell buildup in the retina.
In addition, corticosteroids help stabilize the blood-retina barrier. They do this by affecting molecules involved in fluid and ion balance. They also strengthen the tight junctions between retinal cells. This makes corticosteroids especially effective at reducing macular edema.
Corticosteroids for retinal conditions are delivered in several ways. Each method is designed to get the medication as close to the affected tissue as possible. The main options include:
- Intravitreal implants, which are placed inside the eye and slowly release medication over weeks or months
- Intravitreal injections (injections directly into the gel-filled space inside the eye)
- Intracameral injections, which place medication in the front chamber of the eye after surgery
Specific Medications Used in Retinal Care
Ozurdex (dexamethasone intravitreal implant, 0.7 mg) is a small, biodegradable implant placed inside the eye during an office procedure. Once implanted, it slowly releases dexamethasone over several weeks. The FDA has approved Ozurdex for the treatment of diabetic macular edema and macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). It is also approved for noninfectious uveitis affecting the posterior segment of the eye.
Ozurdex was first approved in June 2009 for macular edema after RVO. It later received approval for posterior uveitis in September 2010 and for DME in the general population in 2014.
Iluvien (fluocinolone acetonide intravitreal implant) and Yutiq (fluocinolone acetonide intravitreal implant) are long-acting implants. They release very small, controlled doses of corticosteroid over an extended period. Iluvien is approved for DME in patients who have been previously treated with corticosteroids and did not have a significant rise in eye pressure. Yutiq is approved for chronic noninfectious uveitis affecting the posterior segment.
These implants are especially useful for patients with chronic inflammatory conditions. They provide steady, long-term medication delivery without frequent injections.
Triamcinolone acetonide is an injectable corticosteroid that a retina specialist can administer directly into the eye. It is used to treat macular edema resulting from diabetic retinopathy, retinal vein occlusion, and uveitis. While effective, it requires repeat injections. It also carries the risk of elevated eye pressure and cataract formation, which are common side effects of corticosteroid use inside the eye.
Dexycu (dexamethasone intraocular suspension) is a formulation designed to treat inflammation after cataract surgery. It is injected into the front chamber of the eye at the end of surgery. There it forms a small sphere that slowly releases dexamethasone over about 30 days. The FDA approved Dexycu in 2018. This approach reduces the need for post-surgical eye drop regimens, which some patients find difficult to follow.
How Anti-Inflammatory Medications Compare to Anti-VEGF Therapy
Anti-VEGF agents such as Eylea (aflibercept), Lucentis (ranibizumab), and Vabysmo (faricimab) work by blocking vascular endothelial growth factor. This reduces abnormal blood vessel growth and leakage. These agents are used primarily for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Anti-inflammatory medications target the broader inflammatory process. This includes prostaglandins, leukotrienes, and multiple immune signaling pathways. Both types of treatment aim to reduce fluid in the retina and protect vision, but they do so through different mechanisms.
In conditions like diabetic macular edema, a retina specialist may choose between these therapies or use them together. Corticosteroids are sometimes considered when anti-VEGF injections alone have not adequately controlled swelling. The choice depends on how a patient responds and other individual factors.
Some newer retinal medications have been associated with inflammatory side effects. Beovu (brolucizumab), an anti-VEGF agent approved for wet age-related macular degeneration, has been linked to cases of retinal vasculitis (inflammation of blood vessels in the retina).
The American Society of Retina Specialists (ASRS) has also received reports of at least six cases of occlusive retinal vasculitis following injection of Syfovre (pegcetacoplan), a complement inhibitor. Syfovre is approved specifically for geographic atrophy, the advanced form of dry age-related macular degeneration. It is important to note that dry AMD and wet AMD are different conditions requiring different treatments. These vasculitis events were observed between 7 and 13 days after injection (ASRS, 2023).
These reports highlight why retina specialists carefully monitor patients after any intravitreal treatment. Anti-inflammatory strategies may be an important part of overall retinal care.
What to Expect During Treatment
If a retina specialist recommends a corticosteroid implant or injection, the appointment typically takes place in the office. The eye will be numbed with anesthetic drops or a local anesthetic. The surface of the eye and the surrounding skin are cleaned with an antiseptic solution to reduce the risk of infection. The process is brief, usually lasting only a few minutes.
Patients may feel a sensation of pressure during the injection. Some mild discomfort, redness, or a gritty feeling is common in the hours following the procedure. These symptoms usually resolve within a day or two. The retina specialist may ask the patient to use antibiotic eye drops for a short period to prevent infection.
For topical NSAID eye drops, treatment is straightforward. Patients use the drops at home according to a prescribed schedule. This often starts a day or two before surgery and continues for several weeks after.
Anti-inflammatory medications, particularly corticosteroids given inside the eye, require regular monitoring. Corticosteroids can raise intraocular pressure (the fluid pressure inside the eye). This may increase the risk of glaucoma. They can also accelerate cataract formation. A retina specialist will check eye pressure and examine the retina at follow-up visits to watch for these side effects and to assess how well the medication is working.
Living With Retinal Inflammatory Conditions
Many retinal conditions that involve inflammation are chronic. This means they require ongoing monitoring and may need repeated treatments. Patients should understand that the goal of treatment is to control inflammation and protect vision over time. Consistent follow-up appointments allow a retina specialist to adjust the treatment plan as needed.
Between appointments, patients can support their eye health in practical ways. Keeping blood sugar well controlled is critical for patients with diabetes. High blood sugar directly contributes to retinal inflammation and vessel damage. Taking all prescribed medications on schedule, including eye drops, helps maintain steady control of inflammation.
Wearing sunglasses outdoors protects the eyes from UV exposure. Eating a diet rich in leafy green vegetables, fish, and other sources of omega-3 fatty acids may support overall eye health. However, diet alone cannot treat retinal disease.
When to See a Retina Specialist
Any patient diagnosed with a retinal inflammatory condition should see a retina specialist regularly, even when vision seems stable. Inflammation can be present without obvious symptoms. Early detection of changes allows for prompt treatment adjustments.
Certain symptoms require immediate attention. See a retina specialist or go to the emergency room right away if you experience any of the following:
- A sudden increase in floaters (spots or strings drifting across your vision)
- Flashes of light in one or both eyes
- A shadow or curtain spreading across your field of vision
- Sudden blurred or distorted vision in one eye
- A rapid decrease in vision after a recent eye injection or procedure
Inflammation can develop or worsen months after intravitreal therapy has started. Some patients experience new floaters or decreased vision. Others may have no symptoms even when inflammation is active. Reporting any changes to a retina specialist promptly is essential.
Questions and Answers
NSAIDs block the production of prostaglandins, one specific group of inflammatory chemicals. They are most commonly used as eye drops around the time of cataract surgery. Corticosteroids are more powerful and block multiple inflammatory pathways at once. They are available as injections and implants placed inside the eye. They are used for conditions like diabetic macular edema, retinal vein occlusion, and uveitis. A retina specialist will choose the right type based on the specific condition and severity of inflammation.
Yes. In some cases, a retina specialist may combine corticosteroid treatment with anti-VEGF injections such as Eylea (aflibercept) or Vabysmo (faricimab). This approach can be helpful when macular edema has not responded well enough to anti-VEGF therapy alone. The combination targets both the abnormal blood vessel growth driven by VEGF and the broader inflammatory response affecting the retina. It is important to note that anti-VEGF injections are used specifically for wet AMD and are not a treatment for dry AMD.
The two most common side effects of corticosteroids inside the eye are elevated intraocular pressure and cataract formation. Elevated eye pressure can increase the risk of glaucoma if it is not detected and managed. Cataract progression may occur more quickly in patients receiving long-term corticosteroid treatment. A retina specialist will monitor eye pressure and lens clarity at regular follow-up appointments. The treatment plan can be adjusted if these issues develop.
The duration depends on the specific implant. Ozurdex (dexamethasone) is biodegradable and releases medication over several weeks. It typically requires replacement every few months. Iluvien (fluocinolone acetonide) and Yutiq (fluocinolone acetonide) are designed for much longer-term release. They deliver a controlled dose of medication for up to three years. The choice of implant depends on the condition being treated, its severity, and how well a patient tolerates corticosteroids.
Topical NSAID eye drops are effective for managing inflammation after cataract surgery. They also reduce the risk of postoperative cystoid macular edema. However, for more serious retinal conditions like diabetic macular edema, retinal vein occlusion, or uveitis, eye drops alone are generally not sufficient. These conditions typically require intravitreal injections or implants to deliver medication directly to the retina. A retina specialist can determine the most appropriate treatment approach.